R od-shaped cells at the back of our eyes allow us to see in dim light. Each day, around dawn, these rod cells shed their tips (LaVail, 1976) , and the lost material is replaced with newly built proteins and other macromolecules made further down in the same cell (Anderson et al., 1980; Young, 1967) .
Cancer cells growing in a tumor also have a high demand for newly built macromolecules. In the early 1920s, the German physiologist Otto Warburg reported on a specialized type of metabolism that converts most of the glucose taken up by a cell into lactate, rather than carbon dioxide and water as usually happens, even when oxygen is abundant (Warburg et al., 1924) . Two of the tissues in which Warburg discovered this type of metabolism, which is often referred to as "aerobic glycolysis", were the very same tissues introduced above, retinas and tumors.
The building of complex macromolecules from simpler building blocks is referred to as anabolism. Recently studies into the metabolism of cancer cells have begun to reveal biochemical details that may link aerobic glycolysis and anabolic activity (Vander Heiden and DeBerardinis, 2017) . One of the remarkable features of cancer cells discovered in these studies is that they often produce specific versions (or isoforms) of the enzymes that carry out glycolysis, namely pyruvate kinase (PKM2) and lactate dehydrogenase (LDHA). Not surprisingly, these same isoforms are present in rod cells (Casson et al., 2016; Lindsay et al., 2014; Rajala et al., 2016; Rueda et al., 2016) . Now, in eLife, Constance Cepko and colleagues at Harvard Medical School -including Yashodhan Chinchore as first author -report how these two glycolytic enzymes contribute to anabolic metabolism in rod cells from mice (Chinchore et al., 2017) .
First, Chinchore et al. inactivated LDHA and PKM2 in mouse rod cells, either with inhibitors or by reducing expression of the genes that encode the enzymes. The resulting rod cells were shorter than normal, as if they did not have enough anabolic activity to counteract the shedding of their tips ( Figure 1 ). In support of this idea, when the mice were kept in constant darkness (which suppresses shedding and renewal of the outer segments), inactivating LDHA or PKM2 had less of an effect. Chinchore et al. then engineered mice in which some cells in the retina made less LDHA or PKM2 while the others were normal. In these 'mosaic' retinas, the only rods that were shorter were the ones with less LDHA or PKM2. This suggests that the enzymes promote anabolism only in the cell in which they are made.
Chinchore et al. were concerned that the complete loss of PKM2 or LDHA might have effects that were so devastating that even the essential 'housekeeping' roles of glycolysis in the cell could be compromised. To address that concern, they also used a more 'surgical' approach that specifically slowed glycolysis without eliminating the entire pathway. Fructose-2,6-bisphosphate is an activator of glycolysis. Previous studies showed that these enzymes can be regulated by tyrosine phosphorylation to promote aerobic glycolysis (Hitosugi et al., 2009; Jin et al., 2017) . Moreover, exposure to lightwhich increases the need for anabolic activityenhances phosphorylation of PKM2 in the retinas of mice (Rajala et al., 2016) . Chinchore et al. confirmed this result and then looked for signaling pathways that, when blocked, reduced how much PKM2 was phosphorylated in rod cells. They found that the pathway that responds to fibroblast growth factor (FGF) can control the phosphorylation of PKM2 and LDHA in mouse retinas. The tissue that normally is immediately adjacent to the rod cells, the retinal pigment epithelium, can influence the amount of FGF that a retina is exposed to in an eye. Chinchore et al. found that culturing mouse retinas with this tissue, or with some FGF, boosts how much lactate is produced.
By manipulating the expression of genes involved in aerobic glycolysis in mouse retinas, Chinchore et al. have further revealed how aerobic glycolysis relates to anabolic metabolism. They also show that disrupting any of three different steps in glycolysis can diminish anabolic capacity and cause the rod cells to become shorter. Each of the disruptions tested would have a different biochemical effect on the glycolytic pathway, but what they have in common is that they all cause less lactate to be produced. It is not yet clear why this would compromise anabolic activity, but the genetic tools developed by Chinchore et al. to manipulate glycolysis in rod cells provide new opportunities to answer this question. 
